Table 1.
Summary of patient, tumor and treatment characteristics.
| Characteristics | n = 10 |
|---|---|
| Median age, years (range) | 40.0 (29.0 – 69.0) |
| Gender | |
| Male Female |
3 (30.0%) 7 (70.0%) |
| WHO Tumor Classification | |
| GBM, IDH-wild type Astrocytoma, IDH-wild type, grade 3 Astrocytoma, IDH-mutant, grade 4 Astrocytoma, IDH-mutant, grade 3 Oligodendroglioma, IDH-mutant, 1p/19q co-deleted |
4 (40.0%) 2 (20.0%) 2 (20.0%) 1 (10.0%) 1 (10.0%) |
| MGMT Promoter Methylation | |
| Unmethylated Unknown |
4 (40.0%) 6 (60.0%) |
| Surgery | |
| Gross Total Resection Subtotal Resection Biopsy |
1 (10.0%) 8 (80.0%) 1 (10.0%) |
| Median no. days from surgery to start of radiation (range) | 23.5 (12.0 – 39.0) |
| Fractionation Scheme | |
| 60 Gy/30 fractions 59.4 Gy/33 fractions 54 Gy/30 fractions |
7 (70.0%) 1 (10.0%) 2 (20.0%) |
| Median % fractions completed on MRL (range) | 96.8 (70.0 – 100.0) |
| Mean in-room time in minutes per fraction* (range) | 37.3 (24.0 – 51.0) |
| Mean in-room time in minutes per fraction including post-beam research imaging (range) | 42.9 (25.0 – 69.0) |
| Radiation Re-plan During Treatment | |
| Yes No |
3 (30.0%) 7 (70.0) |
| Chemotherapy | |
| Concurrent TMZ Adjuvant TMZ |
9 (90.0%) 10 (100.0%) |
GBM, Glioblastoma; MRL, high-field MR-Linac; TMZ, Temozolomide.
*Excluding post-beam research imaging.